Investment Summary |
|
|---|---|
| Date | 2016-01-14 |
| Target | Isomerase Therapeutics |
| Sector | Life Science |
| Investor(s) | Abliva |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Medical Products |
| Employees | 7 |
| Revenue | 8M SEK (2014) |
Abliva is a medicine company discovery and development of medical products. Abliva was founded in 2000 and is based in Lund, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Stake Purchase M&A Deals | 1 of 1 |
| Country: United Kingdom M&A | 2 of 2 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-03-11 |
Biotica - Highly Potent Novel Cyclophilin Inhibitors
Cambridge, United Kingdom Biotica Ltd. - Highly Potent, Novel Cyclophilin Inhibitors includes novel cyclophilin inhibitors is from a new class of molecules called Sangamides based on a novel and unique chemistry platform of polyketides around which NeuroVive has also acquired the intellectual property rights. These novel cyclophilin inhibitors are expected to form the basis of the next-generation of NeuroVive products for a broad range of diseases including cardio- and neuroprotection. |
Buy | - |
